CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
Leia M. Smith(Seagen (United States)), P. J. Carter(Seagen (United States)), Mechthild Jonas(Seagen (United States)), Roger F. Zabinski(Seagen (United States)), Albina Nesterova(Seagen (United States)), Martha E. Anderson(Seagen (United States)), K L Van Orden, H-P Gerber(Seagen (United States)), Steven M. Ruben(Human Genome Sciences (United States)), Steven Duniho(Seagen (United States)), Maureen C. Ryan(Seagen (United States)), May Kung Sutherland(Seagen (United States)), Paul A. Moore(Zymeworks (Canada))
Cited by 289
Related Papers
Mutation of a <i>mutL</i> Homolog in Hereditary Colon Cancer
|Science|1994|1.8k
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
|Nature Biotechnology|2015|521